Baudax Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Principles (Policies)
Notes Tables
Notes Details

Intangible Assets

Intangible Assets

6 Months Ended

Jun. 30, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

(9)	Intangible Assets

The following represents the balance of the intangible assets at June 30, 2020:

	Cost		Accumulated Amortization		Net Intangible Assets
Asset resulting from R&D activities	$	26,400	$	859	$	25,541
Total	$	26,400	$	859	$	25,541

Amortization expense for the three and six months ended June 30, 2020 was $644 and $859, respectively. There was no amortization expense for the three and six months ended June 30, 2019.

As of June 30, 2020, future amortization expense is as follows:

	Amortization
Remainder of 2020	$	1,288
2021		2,576
2022		2,576
2023		2,576
2024 and thereafter		16,525
Total	$	25,541